Overview

Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Hypothesis Response guided therapy improves significantly the overall SVR in Hispanics compared to historical control. There is no difference in SVR between patients with an undetectable HCV RNA at week 8 and week 28 who received a 4 week lead-in of PR plus 24 weeks of PR+BOC based treatment and patients with detectable HCV RNA at week 8 and undetectable HCV RNA at week 24 who received a lead-in of PR plus 32 weeks PR+BOC followed by based therapy and 12 weeks of PR.
Details
Lead Sponsor:
Arrowhead Regional Medical Center
Treatments:
Peginterferon alfa-2b
Ribavirin